01 August 2009
Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity
Stamatios E TheocharisABDEF, Jerzy T KlijanienkoBC, Elianne PadoyB, Stavros AthanassiouCD, Xavier X Sastre-GarauADMed Sci Monit 2009; 15(8): BR221-226 :: ID: 878132
Abstract
Background
Focal adhesion kinase (FAK) is an enzyme of the tyrosine kinase group linked to signaling pathways between cells and the extracellular matrix. In tumor cells in vitro, FAK expression correlated with their ability for invasion and metastasis. Additionally, in vivo FAK has been implicated in malignant transformation and disease progression. The aim of the present study was to evaluate the clinical significance of FAK expression in breast ductal invasive carcinoma (DIC).
Material and Method
Immunocytochemical techniques were used to assess FAK expression on cytological material obtained from 73 patients with breast DIC. FAK expression status (positivity, overexpression, and intensity of immunostaining) was compared with clinicopathological parameters and the tumor cells' proliferative capacity.
Results
Sixty-four of the 73 DIC cases (88%) were FAK positive and FAK protein overexpression was noted in 15 of the 73 (21%). In the DIC cases examined, FAK positivity correlated with tumor size (p=0.016) and FAK protein overexpression with tumor histological grade (p=0.034) and the tumor cells' proliferative capacity (p=0.003). The intensity of FAK protein staining did not significantly correlate with any of the examined clinicopathological parameters.
Conclusions
In breast DIC it becomes evident that FAK protein positivity and overexpression correlate with important clinicopathological parameters. Further molecular and clinical studies are required to delineate the significance of FAK as a factor for better prognosis and management of breast cancer patients.
Keywords: Focal Adhesion Protein-Tyrosine Kinases - metabolism, Cytoplasm - pathology, Carcinoma, Ductal, Breast - pathology, Breast Neoplasms - pathology, Aged, 80 and over
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952